Preclinical evaluation of $[^{18}\text{F}]$FDG-PET as a biomarker of lymphoid tissue disease and inflammation in Zika virus infection

Carla Bianca Luena Victorio\textsuperscript{1} · Joanne Ong\textsuperscript{1} · Jing Yang Tham\textsuperscript{1} · Marie Jennifer Reolo\textsuperscript{1} · Wisna Novera\textsuperscript{1} · Rasha Msallam\textsuperscript{1} · Satoru Watanabe\textsuperscript{2} · Shirin Kalimuddin\textsuperscript{2,3} · Jenny G. Low\textsuperscript{2,3} · Subhash G. Vasudevan\textsuperscript{2} · Ann-Marie Chacko\textsuperscript{1} 

Received: 3 March 2022 / Accepted: 25 June 2022 / Published online: 25 July 2022 © The Author(s) 2022

Abstract

Purpose Zika (ZIKV) is a viral inflammatory disease affecting adults, children, and developing fetuses. It is endemic to tropical and sub-tropical countries, resulting in half the global population at risk of infection. Despite this, there are no approved therapies or vaccines against ZIKV disease. Non-invasive imaging biomarkers are potentially valuable tools for studying viral pathogenesis, prognosticating host response to disease, and evaluating in vivo efficacy of experimental therapeutic interventions. In this study, we evaluated $[^{18}\text{F}]$fluorodeoxyglucose ($[^{18}\text{F}]$FDG)-positron emission tomography (PET) as an imaging biomarker of ZIKV disease in a mouse model and correlated metabolic tracer tissue uptake with real-time biochemical, virological, and inflammatory features of tissue infection.

Methods $[^{18}\text{F}]$FDG-PET/CT imaging was performed in an acute, lethal ZIKV mouse infection model, at increasing stages of disease severity. $[^{18}\text{F}]$FDG-PET findings were corroborated with ex vivo wholemount-tissue autoradiography and tracer biodistribution studies. Tracer uptake was also correlated with in situ tissue disease status, including viral burden and inflammatory response. Immune profiling of the spleen by flow cytometry was performed to identify the immune cell subsets driving tissue pathology and enhancing tracer uptake in ZIKV disease.

Results Foci of increased $[^{18}\text{F}]$FDG uptake were consistently detected in lymphoid tissues—particularly the spleen—of ZIKV-infected animals. Splenic uptake increased with disease severity, and corroborated findings in tissue pathology. Increased splenic uptake also correlated with increased viral replication and elevated expression of pro-inflammatory cytokines within these tissues. ZIKV-infected spleens were characterized by increased infiltration of myeloid cells, as well as increased proliferation of both myeloid and lymphoid cells. The increased cell proliferation correlated with increased tracer uptake in the spleen. Our findings support the use of $[^{18}\text{F}]$FDG as an imaging biomarker to detect and track ZIKV disease in real time and highlight the dependency of affected tissue on the nature of the viral infection.

Conclusion $[^{18}\text{F}]$FDG uptake in the spleen is a useful surrogate for interrogating in situ tissue viral burden and inflammation status in this ZIKV murine model.

Keywords $[^{18}\text{F}]$FDG · Zika · Viral infection · Dengue · AG129 mouse · Viral inflammation

Introduction

Zika virus (ZIKV) is a mosquito-transmitted infection affecting developing fetuses, children, and adults. It causes sporadic outbreaks, the largest of which occurred in 2015 and was declared a public health emergency of international concern by the World Health Organization (WHO) [1]. Half of the global population is currently at risk of infection and live in tropical and subtropical regions where Aedes mosquitoes—the vector responsible for the transmission of ZIKV—are endemic [2, 3]. With global climate change,
rapid population growth in the tropics, and an expected return to high-volume air travel in the post-COVID pandemic era, even more people will be at risk of exposure to such mosquito-borne viruses. Despite the continued public health threat of ZIKV, no therapeutics or vaccines are approved for human use. Various vaccine candidates and antivirals were developed and evaluated in clinical trials (reviewed in [4, 5]) but met with various challenges in recent years. Vaccine and therapeutic efficacy trials are hampered by the difficulty in patient recruitment due to the low natural ZIKV infection rates and require controlled deliberate infection of trial participants [6]. Moreover, global efforts in vaccine development have been dampened by refocusing of resources towards the current COVID pandemic.

One way to expedite the bench-to-bedside development of these therapies is by employing non-invasive imaging biomarkers. These facilitate spatial localization of viral disease (or disease severity) and enable deeper in situ molecular insights into disease pathogenesis. This is not attainable with the current diagnostic gold standard of detecting active viral replication in peripheral blood using polymerase chain reaction (PCR) [7]. Imaging biomarkers that correlate with disease progression have the potential to predict response to therapy and rapidly inform go or no-go decisions in drug evaluations. This is most relevant in the context of developing therapeutics against highly virulent and lethal pathogens—such as Ebola and Nipah viruses—but is nonetheless relevant to ZIKV and other related flavivirus diseases, including the endemic dengue virus (DENV) [8]. Therefore, there is a real clinical need to identify and characterize infectious disease-related imaging biomarkers [9].

We previously identified 18F-fluorodeoxyglucose ([18F]FDG) uptake as a preclinical imaging biomarker for early prediction of response to therapeutic interventions for DENV infection. Lesions of increased [18F]FDG uptake in the intestines were found to correlate with disease severity, tissue viral burden, and expression of inflammatory cytokines in lethal and non-lethal mouse models of DENV infection [10]. Clinical [18F]FDG-PET also distinguishes infection-mediated tissue inflammation patterns, namely, in lymphoid tissues, in DENV patients during early disease [11, 12]. In contrast, there have been no reports of [18F]FDG-PET imaging in ZIKV disease, in either humans or animal models.

Here we examined [18F]FDG uptake in the lymphoid organs of a murine model of acute lethal ZIKV disease. The spatial and temporal dynamics of metabolic tracer uptake in ZIKV were also compared with DENV to identify common tissue-specific imaging biomarkers between these two related viruses. Tissue uptake in ZIKV was further correlated with pathology and markers of viral disease and inflammation in tissues. This study demonstrates that splenic [18F]FDG uptake is a robust surrogate for interrogating of tissue viral burden and inflammation status in ZIKV.

Methods

Study ethics

Animal experiments (protocol 2016/SHS/1197) were performed with approval from the Institutional Animal Care and Use Committee (IACUC) of Singapore Health Services and conformed to the US National Institutes of Health (NIH) guidelines and public law.

Animal infection models

Male AG129 mice, deficient in expression of receptors for type I and type II interferons, were obtained from an in-house breeding colony, and subsequently used for infection studies at 8–11 weeks of age. This transgenic mouse model is the classic murine model for flavivirus infection, as wild-type mouse strains that normally express type I/II interferons are not susceptible to ZIKV and DENV infections [13, 14]. Moreover, the potent antiviral effects of type I/II interferons significantly dampen the infection, replication, and dissemination of these viruses [15, 16]. Lethal infection models were generated using either a clinical ZIKV strain Paraiba01/2015 (GenBank Accession No. KX280026.1) isolated from an anonymous patient in the state of Paraiba, Brazil (a kind gift from Dr. Pedro Vasconcelos (Instituto Evandro Chagas, Brazil)), or using mouse-adapted DENV2 strain S221 [17] (a gift from Prof. Sujan Shresta (La Jolla Institute for Allergy and Immunology, USA)).

The ZIKV mouse model was established by intraperitoneal (i.p.) injection of 105 pfu of ZIKV as described previously [18–20]. Mouse infections with DENV were performed as previously described [10, 19]. Briefly, mice were injected intravenously (i.v.) with DENV2 S221 (5 × 104 pfu) complexed with 4G2 mouse monoclonal antibody (mAb; 20 μg) that targets the flavivirus envelope protein.

The study timelines and selection of disease stages for experimental procedures are summarized in Fig. 1a. The time points for the assays were selected based on the Kaplan–Meier survival curves and body weight monitoring of each disease model (Fig. S1a, b). Late disease was designated as the time point when the animals started dying from disease—i.e., day 8 for the ZIKV model and day 4 for the DENV model (Fig. S1a). Meanwhile, mid disease was designated as the midpoint between pre disease and late disease and also coincides with when the animals began losing significant weight (Fig. S1b).
[18F]FDG-PET/CT image acquisition, image reconstruction, and image analysis

[18F]FDG-PET/CT imaging in mice was performed as described previously [10]. Briefly, mice were fasted overnight (~12 h), sedated with 2% isoflurane, and i.v. injected with 40 MBq [18F]FDG (Singapore Radiopharmaceuticals, Singapore). Following a 1-h uptake phase, mice underwent total body PET scan for 40 min (VECTOR4CT, MILabs, Netherlands) using the M7 UHR 0.7-mm pinhole collimator, immediately followed by total body accurate CT scan for 5 min (tube current, 0.24 mA; tube voltage, 50 kV). The resulting images were reconstructed at a voxel resolution of 0.8 mm using a SROSEM algorithm with 8 subsets, 12 iterations, and a 1.6-μm Gaussian filter. The PET and CT image co-registration was automatically handled by the MILabs image reconstruction software package. Similarly, attenuation correction of the PET image was done automatically with the software using the CT image.

Image analysis was performed using PMOD v3.7 (PMOD Technologies, Switzerland). Volumes of interest (VOIs) were drawn on CT images for lymph nodes and guts and transferred to PET images. Spleen VOIs were drawn using both CT and PET images and subjected to iso-contouring using a minimum threshold of SUV = 1.0—the count rate when a given activity is uniformly distributed within a body phantom (or VOI). Gut VOIs were drawn around the abdominal cavity using CT as a guide and excluding the PET signals from both kidneys and spleen. The mean standardized uptake value (SUV) was defined as the average of all voxels in the VOI.

Ex vivo digital autoradiography and biodistribution of [18F]FDG uptake in virus-infected tissues

Infected mice were injected i.v. with 10 MBq [18F]FDG and tissues were harvested following a 60-min tracer uptake. Freshly isolated wholemount lymphoid tissues were immediately exposed to multi-purpose phospho-screen (BAS-IP MS) for 30 min. Fresh tissues with high tracer uptake were exposed to super-resolution (BAS-IP SR) phosphoscreen for 5 min (GE Healthcare Life Sciences, USA). [18F]FDG standards at 2/3 serial dilution from 600 to 0 kBq were mounted together with mouse tissue for calibration of digital autoradiography (DAR) images. Screens were then scanned using the Sapphire Biomolecular Imager (Azure Biosystems, USA) at 100-μm resolution. Images were processed and analyzed using ImageJ software (National Institutes of Health, USA). Following DAR, tissues were subjected to gamma counting (2470 Wizard2, PerkinElmer, USA).

Tissue viral loads and pro-inflammatory cytokine expression

Tissues were harvested immediately after PET/CT imaging and stored in −80 °C. Frozen tissues were homogenized, and viral RNA was extracted using QIAamp Viral RNA Mini Kit (Qiagen, Germany). Real-time qRT-PCR was carried out using primers and protocols as described previously [19]. Cytokine expression was also measured from homogenized frozen tissues using Ready-Set-Go! ELISA kits for murine TNF-α and IL-6 and following the manufacturer’s recommended protocols (eBioscience, USA).

Immune profiling of spleen tissues

Tissue immune profiling was conducted as previously described [21, 22]. Briefly, spleens were harvested, mechanically disaggregated, and incubated in digestion buffer containing DNased and collagenase. Following homogenization, single-cell suspensions of splenocytes were collected by passing the suspension through a nylon mesh strainer (70 μm). Cells were labeled with fluorescent antibody cocktails, and immune cell subsets were gated and identified by flow cytometry (Fortessa, BD Biosciences, USA) and analyzed using FlowJo V10.8.0 (Becton Dickinson & Company (BD), USA). Detected events were normalized to absolute cell number using CountBright Absolute Counting Beads (Thermo Fisher, USA) [23]. The following markers were used: DAPI− (live cells), CD45+ (total hematopoietic cells or immune cells), Ly6G+Ly6C+CD11b+ (granulocytes); CD11b+F4/80+Ly6c+Ly6G−CD3− (monocyte-derived macrophages), CD11b+CD115+ (total monocytes), CD11c+MHCII+ (conventional dendritic cells), CD3−CD19+B220+MHCII+ (B cells), CD19−CD49b−B220−LY6G−CD3+ (cytotoxic T cells), and CD19−CD49b−B220−LY6G−CD3+CD8+ (helper T cells).

Statistical analysis

Statistical analyses and graphing were performed with Prism v8.0 (GraphPad Software, USA). Non-parametric Kruskal–Wallis test with Dunn’s post-hoc correction was used to compare means, and Spearman’s coefficient (ρ) was used to assess the correlation between tissue [18F]FDG uptake and various parameters. The best-fit linear regression trend of the scatter plots and 95% confidence interval (CI) for the regression line were also computed. Results were considered statistically significant at p < 0.05.
Results

$[^{18}F]$FDG-PET/CT imaging in acute and lethal ZIKV

We infected AG129 mice with ZIKV and injected the animals with $[^{18}F]$FDG to investigate tissue-specific changes in tracer uptake that could be correlated with various aspects of disease progression. The study schedule was optimized to capture disease- and host response-related biomarker dynamics at increasing stages of disease severity (Fig. 1a). PET/CT was performed at pre-infection (day 0), mid-disease (day 4), and late-disease (day 8) in the ZIKV model (Fig. 1a). In the comparable DENV model [10], mid and late diseases were reflected on days 2 and 4 post-infection, respectively. We compared $[^{18}F]$FDG uptake in ZIKV to our previously published $[^{18}F]$FDG-PET/CT findings in DENV [10], re-analyzed with respect to lymphoid tissues.

The salient feature in the ZIKV $[^{18}F]$FDG-PET/CT maximum intensity projection (MIP) images was the increased tracer uptake in lymphoid tissues, particularly the spleen (spl) and axillary lymph nodes (Ax.LN), at mid disease (day 4 post-infection) (Fig. 1b-d). No detectable signal was observable in the bone marrow (i.e., femur and spine). The most striking organ-specific tracer uptake in the DENV model was from the gut (int), which increased over time.
Ex vivo DAR and biodistribution of [18F]FDG in infection models

Increased [18F]FDG uptake in lymphoid tissues was also observed by ex vivo tissue wholemount DAR images, which revealed elevated tracer uptake in spleens (spl) and lymph nodes (Ax.LN, Cer.LN, In.LN) of both ZIKV and DENV mice at late disease (Fig. 3a). Expectedly, hotspots of high tracer uptake were also detected in metabolically active tissues—brain (br) and heart (h)—in both models (Fig. 3b). Moreover, no uptake was detected in the stomach (st) and intestines (S.Int, L.Int) from ZIKV animals, which was in stark contrast to DENV (Fig. 3b; Table S1). These uptake patterns are consistent with the observed changes in gross pathology in ZIKV-infected testes (tes) (Fig. 3c) despite observations in DAR. Meanwhile, the increased tracer distribution in the digestive tissues of DENV mice, and its lack thereof in ZIKV mice, was consistent with observations from both PET and DAR (Figs. 1b and 3b, c). More relevant to this study is the increased uptake in lymphoid tissues in both ZIKV and DENV disease. Notably, [18F]FDG in ZIKV spleens was 879% higher than pre-infection spleens (1.54 vs 0.16% ID, respectively; p = 0.0001), while uptake in DENV spleens was 1400% higher than uptake in pre-infection spleens (2.37% ID, p = 0.0007) (Fig. 3c; Table S2). All lymph nodes collected also registered higher uptake in disease as compared to pre-infection control. FDG activity in ZIKV Ax.LN was 305% higher than activity detected in pre-infection (0.07 vs. 0.02% ID, p = 0.03), while the amount of tracer detected in DENV Ax.LN (0.08%ID) was 306% higher than in the control group (p = 0.005) (Fig. 3c; Table S2). In general, tissue biodistribution corroborated the findings from PET imaging, particularly in the intestines, spleen, and lymph nodes. However, one difference was observed in the bone marrow. PET imaging could not distinguish changes in ZIKV bone uptake in the spine or other long bones in infected mice, and this was confirmed with biodistribution studies. In contrast, a significant increase in [18F]FDG uptake in femur bones was only observed by gamma counting in DENV mice at late disease relative to pre-infection (0.25 vs. 0.10% ID; p = 0.01) (Fig. 3c; Table S2). However, it is unclear whether the bone uptake is due to free 18F-fluoride in the bone or due to a possible lymphoid inflammatory response within the bone marrow.

Correlation of [18F]FDG PET and ZIKV disease status in lymphoid tissues

Active viral replication is a principal contributor to pathology and ultimately death in preclinical models. Hence, we compared [18F]FDG SUV to ZIKV viral burden in tissues. In ZIKV spleen, viral burden at mid disease and late disease was 11,500-fold higher (p < 0.0001) and 5000-fold higher (p < 0.0001) than at pre-infection, respectively, and strongly correlated with tracer uptake (ρ = 0.66; p = 0.007) (Fig. 4a). In addition, despite viral burden in DENV spleen being 100–200-fold less than in ZIKV spleen, viral load also strongly correlated with tissue uptake in DENV (ρ = 0.71; p = 0.001) (Fig. 4a). These indicate that [18F]FDG uptake in the spleen is a sensitive indicator of viral burden in ZIKV, as well as in DENV.

Tissue inflammation is associated with ZIKV disease, particularly within the brain, gonads, and eyes, as observed in various preclinical models. Expression of pro-inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in ZIKV spleen at both mid and late disease was two-fold to three-fold higher than pre-infection (Fig. 4b, c). Additionally, both cytokines showed a strong correlation with [18F]FDG uptake (IL-6: ρ = 0.67; CI: 0.27–0.88; p = 0.004; TNF-α: ρ = 0.84; CI: 0.59–0.94; p < 0.0001), confirming that uptake in ZIKV spleens was also a sensitive indicator of tissue inflammation status. This contrasted with DENV, where only IL-6 exhibited a strong correlation with [18F]FDG PET signals in the spleen (ρ = 0.72; CI: 0.38–0.89;
Despite IL-6 and TNF-α having more exaggerated expression in DENV spleens relative to ZIKV (8–14-fold higher than pre-infection) (Fig. 4b,c), the expression of both IL-6 and TNF-α declined over the course of disease and did not exhibit any correlation with tissue uptake (Fig. S2a, b). These results indicate that [(18F)FDG] uptake in ZIKV Ax.LN can only be used as an indicator of tissue viral replication but not of inflammation status.

Immune profiling of ZIKV virus-infected spleens

The immune cell landscape within the spleen was assessed by flow cytometry at various stages of disease to examine
Fig. 4 Contribution of tissue viral burden and inflammation status on spleen [18F]FDG uptake in acute ZIKV and DENV disease. a, c Fold change in expression at mid and late disease relative to pre-infection, and correlation between [18F] FDG uptake and either a tissue viral load, b IL-6 expression, or c TNF-α expression in diseased spleens. Spleens from two independent experiments were harvested from ZIKV mice at mid disease (n = 10) and late disease (n = 10), and DENV mice at mid disease (n = 5) and late disease (n = 5). Spleens from pre-infection mice (n = 10) were also obtained from two independent experiments. Data are presented as mean ± SD. Multiple comparison of means was performed using Kruskal–Wallis test with Dunn’s post-hoc correction. *p < 0.05. **p < 0.005. ***p < 0.0005. ****p < 0.00001. ns, not significant. Solid lines indicate the best-fit linear regression trend of the scatter plots, and dotted lines indicate the 95% CI for the regression line. ρ, Spearman correlation coefficient.
which cell subsets may be driving increased FDG uptake. The total numbers of immune cells in ZIKV spleens, marked as CD45⁺, did not change over time (Fig. 5a). In contrast, the total number of non-immune cells (CD45⁻) in ZIKV spleens increased at late disease. However, these cells account for only a small fraction (<10%) of total cells (CD45⁺ and CD45⁻) in the spleen (Fig. S5a). The CD45⁺ erythrocytes, which may have contributed significantly to the splenomegaly observed in ZIKV-infected mice (Fig. S1c), were not included in this analysis and were lysed during tissue processing. Deeper cell profiling revealed that the subset of CD45⁺ cells most dominant in the spleen are the lymphocytes—mainly the B and T cells—whose absolute cell counts declined in ZIKV infection especially at late disease (Fig. 5c). However, this decline was compensated by concomitant increase in myeloid cell populations infiltrating from the bone marrow, which include granulocytes, monocytes, dendritic cells, and monocyte-derived macrophages (Mo-MAC) (Fig. 5c). The increased demand for immune repopulation of the diseased spleen is being fulfilled by the bone marrow as revealed by the rapid tenfold increase in total bone marrow cell counts most likely contributed by hematopoiesis and proliferation (Fig. S3).
Assessment of the cell proliferation status in ZIKV spleens revealed a peak in CD45+ immune cells expressing the proliferation marker ki67 at mid disease. This increase was sixfold higher compared to CD45− cells (Fig. 5a). Further, there was a strong correlation between [18F]FDG uptake and proliferating ki67+ CD45+ spleen immune cells (ρ = 0.92; CI: 0.81–0.97; p < 0.0001) (Fig. 5b). Within the various immune cell subsets, ki67 expression rapidly increased across all lymphocytes and peaked at mid disease (Fig. 5d), suggesting that these cells are actively replacing lymphocytes that presumably died due to infection. Ki67 expression also significantly increased in infiltrating myeloid cells (Fig. 5d), confirming that the increasing total myeloid cell count during disease was due to both cellular infiltration of actively proliferating cells and in situ proliferation in the spleen (Fig. 5c). Taken together, increased proliferation of both myeloid and lymphoid cells within the ZIKV spleen seem to contribute significantly to [18F]FDG uptake.

In contrast to ZIKV, spleens from DENV-infected mice exhibited a rapid decline of CD45+ immune cells (Fig. 5a), primarily contributed by loss of both B and T lymphocytes (Fig. S4a). This disappearance was ineffectively compensated by increased infiltration of myeloid cells (Fig. S4b) supplied by the bone marrow (Fig. S3). Increased ki67 expression in immune cells (Fig. 5a), mainly from lymphocytes (Fig. S3b), also failed to counteract the rapid decline of spleen cells in the tissue. Regardless, ki67 expression on immune cells positively correlated with tracer uptake in the spleen (ρ = 0.55; CI: 0.17–0.79; p = 0.006) (Fig. 5b). Hence, similarly to the observations in ZIKV, immune cell proliferation in the DENV spleen is possibly driving the increased [18F]FDG uptake.

**Discussion**

To date, ZIKV studies have mainly focused on neurological complications resulting from maternal infection, as well as male infertility post-infection. Hence, the effect of ZIKV infection on the induction of the inflammatory response remains poorly understood. In this preclinical study, we investigated how [18F]FDG-PET could serve as a non-invasive imaging biomarker of ZIKV disease and inflammation. The hallmark of murine ZIKV disease in [18F]FDG-PET was high tracer uptake in the lymphatic tissues, especially the spleen and axillary lymph nodes (Ax.LN). Consistent with previous studies [24, 25], ZIKV infection in the spleen resulted in gross tissue enlargement and increased viral replication, with the latter trending intimately with tracer tissue uptake. Additionally, this study demonstrated that there are elevated levels of the pro-inflammatory cytokines IL-6 and TNF-α in the spleen, which correlated strongly with tracer uptake in the tissue. In contrast, [18F]FDG in Ax.LN only correlated with viral burden and not inflammatory response. With marked differences between [18F]FDG uptake and associated ex vivo biomarkers at mid and late disease, early uptake patterns in lymphoid tissues appear to be important in dissecting acute viral ZIKV pathogenesis and host inflammatory response.

The dynamic changes in the immune landscape of ZIKV-infected spleens with increasing disease severity and which immune cell subset/s may be driving the FDG uptake within the tissue have not been studied previously. Here we demonstrate that during ZIKV disease progression, total CD45+ immune cells in the spleen were unchanged while total CD45− non-immune cells increased. Lymphocytes, specifically B and T cells, in the spleen declined during disease, and this is consistent with the known permissiveness of lymphocytes to ZIKV infection [26]. This decline was counterbalanced by increase in myeloid cells (mainly granulocytes, monocytes, monocyte-derived macrophages (Mo-MAC), and dendritic cells) infiltrating the tissue, as supplied by the bone marrow. In addition, immune cell proliferation characterized by increased ki67 expression was found to be significantly elevated in the spleen and strongly correlated with spleen [18F]FDG uptake. This implies that the increased energetic demands of highly proliferating cells may be driving the tracer tissue uptake during disease. Ki67 expression is reported to positively correlate with [18F]FDG uptake in various cancers [27, 28], but this relationship has not been concretely established in the context of infectious disease. A more direct way of resolving which immune cells in the spleen drive [18F]FDG uptake is by measuring the glucose transporter expression. The glucose transporter (Glut-3) specifically directs glucose and [18F]FDG uptake in immune cells and is further upregulated upon immune-cell activation [29, 30]. Subsequent gamma counting of sorted immune cell subsets gated on high Glut-3 expression collected from animals injected with [18F]FDG would then directly identify the specific immune cells driving increased FDG uptake. This method had been described recently in a study aimed at identifying specific cells that take up a radiotracer in the brain [31, 32].

In addition to uptake in lymphoid tissues, we also expected increased [18F]FDG uptake in ZIKV brains and gonads—the tissues known from other mouse ZIKV infection models to be highly permissive to infection [20, 24, 33]. PET/CT could not discriminate uptake in the testes from the bladder, despite seeing trends towards elevated tracer uptake in ZIKV-infected testes through DAR and gamma counting. Therefore, [18F]FDG may not be a reliable imaging biomarker to interrogate disease and inflammation that had been well characterized in ZIKV-infected gonads [34, 35]. Another known complication of ZIKV disease is neuro-inflammation resulting from infection of the central nervous system.
Neither PET/CT, DAR, nor gamma counting registered increased \(^{[18}F\)FDG uptake in ZIKV brains despite strong evidence of neuroinflammation observed in harvested ZIKV brains at late disease (data not shown).

The tracer lacks sensitivity in detecting neuroinflammation due to high basal uptake in normal brain tissues. Imaging approaches targeted to molecular markers of neuroinflammation, such as the translocator protein (TSPO), may be more appropriate tools for interrogating ZIKV infection and host response in the brain [37]. In addition, larger preclinical cohort studies are required to confirm the significance of the \(^{[18}F\)FDG uptake patterns in brain and testes to show their predictive value.

To date, there are no virus-specific molecular imaging biomarkers. Previous attempts to develop DENV-targeted molecular imaging probes using labeled antisense oligonucleotides that bind to DENV genome sequences resulted in disappointing in vitro results and failed to reach preclinical predictive value.

Data availability

All raw data and materials are available upon request.

Conflict of interest

The authors declare no competing interests.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Roos RP. Zika virus—a public health emergency of international concern. JAMA Neurol. 2016;73:1395–6. https://doi.org/10.1001/jamaneurol.2016.3677.

2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496:504–7. https://doi.org/10.1038/nature12060.
3. Messina JP, Brady OJ, Golding N, Kramar MUG, Wint GRW, Ray SE, et al. The current and future global distribution and population at risk of dengue. Nat Microbiol. 2019;4:1508–15. https://doi.org/10.1038/s41564-019-0476-8.

4. Diamond MS, Ledgerwood JE, Pierscion TC. Zika virus vaccine development: progress in the face of new challenges. Annu Rev Med. 2019;70:121–35. https://doi.org/10.1146/annurev-med-040717-051127.

5. Zou J, Shi PY. Strategies for Zika drug discovery. Curr Opin Virol. 2019;35:19–26. https://doi.org/10.1016/j.coviro.2019.01.005.

6. Pattnaik A, Sahoo BR, Pattnaik AK. Current status of Zika virus vaccines: successes and challenges. Vaccines (Basel). 2020;8(2):266. https://doi.org/10.3390/vaccines8020266.

7. Gordon O, Ruiz-Bedoya CA, Ordonez AA, Tucker EW, Jain SK. Molecular imaging: a novel tool to visualize pathogenesis of infections in situ. MBio. 2019;10. doi:https://doi.org/10.1128/mBio.00317-19.

8. Bocan TM, Panchal RG, Bavari S. Applications of in vivo imaging in the evaluation of the pathophysiology of viral and bacterial infections and in development of countermeasures to BSL3/4 pathogens. Mol Imaging Biol. 2015;17:4–17. https://doi.org/10.1007/s11307-014-0759-7.

9. Jain SK. The promise of molecular imaging in the study and treatment of infectious diseases. Mol Imaging Biol. 2017;19:341–7. https://doi.org/10.1007/s11307-017-1055-0.

10. Chacko AM, Watanabe S, Herr KJ, Kalimuthu S, Tham JY, Ong J, et al. 18F-FDG as an inflammation biomarker for imaging dengue virus infection and treatment response. CICI. 2017.2. https://doi.org/10.1172/jici.insight.93474.

11. Kalimuthu S, Xie W, Watanabe S, Tham JY, Sam H, Chan KWK, et al. [18F]-fluorodeoxyglucose positron emission tomography as a window into human dengue pathophysiology. Antiviral Res. 2021;185: 104991. https://doi.org/10.1016/j.antiviral.2020.104991.

12. Jingui J, Kajiya Y, Nakajo M, Nakajo M, Yoshira T. Increased 18F-FDG uptake in the spleen and multiple lymph nodes in dengue fever. Clin Nucl Med. 2016;41:e255–6. https://doi.org/10.1097/RLU.0000000000001110.

13. Morrison TE, Diamond MS. Animal models of Zika virus infection, Pathogenesis, and Immunity. J Virol. 2017;91(8):e00019-17. https://doi.org/10.1128/JVI.00019-17.

14. Lazear HM, Govero J, Smith AM, Platt DJ, Fernandez E, Miner JJ, et al. A mouse model of Zika virus pathogenesis. Cell Host Microbe. 2016;19:720–30. https://doi.org/10.1016/j.chom.2016.03.010.

15. Valadão AL, Aguiar RS, de Arruda LB. Interplay between inflammation and cellular stress triggered by flaviviridae viruses. Front Microbiol. 2016;7:1233. https://doi.org/10.3389/fmicb.2016.01233.

16. Schoggins JW. Interferon-stimulated genes: what do they all do? Annu Rev Virol. 2019;6:567–84. https://doi.org/10.1146/annurev-virology-092818-015756.

17. Yauh LE, Zellweger RM, Koturri MF, Quinbudin A, Sidney J, Peters B, et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol. 2009;182:4865–73. https://doi.org/10.4049/jimmunol.0801974.

18. Watanabe S, Chan KW, Wang J, Rivino L, Lok SM, Vasudevan SG. Dengue virus infection with highly neutralizing levels of cross-reactive antibodies causes acute lethal small intestinal pathology without a high level of viremia in mice. J Virol. 2015;89:5847–61. https://doi.org/10.1128/JVI.00216-15.

19. Watanabe S, Tan NWY, Chan KWK, Vasudevan SG. Dengue virus and Zika virus serological cross-reactivity and their impact on pathogenesis in mice. J Infect Dis. 2019;219:223–33. https://doi.org/10.1093/infdis/jiy482.

20. Aliota MT, Caine EA, Walker EC, Larkin KE, Camacho E, Osorio JE. Characterization of lethal Zika virus infection in AG129 mice. PLoS Negl Trop Dis. 2016;10:e0004682. https://doi.org/10.1371/journal.pntd.0004682.

21. Msallam R, Balla J, Rathore APS, Kared H, Malleret B, Saran WAA, et al. Fetal mast cells mediate postnatal allergic responses dependent on maternal IgE. Science. 2020;370:941–50. https://doi.org/10.1126/science.aba0864.

22. Cossarizza A, Chang HD, Radbruch A, Acs A, Adam D, Adam-Kluges S, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). Eur J Immunol. 2019;49:1457–93. https://doi.org/10.1002/eji.201970107.

23. Villarroya-Beltri C, Gutierrez-Vazquez C, Sanchez-Madrid F, Mittelbrunn M. Analysis of microRNA and protein transfer by exosomes during an immune synapse. Methods Mol Biol. 2013;1024:41–51. https://doi.org/10.1007/978-1-62703-453-1_4.

24. Rossi SL, Tesh RB, Azar SR, Murtuza AE, Hanley KA, Auguste AJ, et al. Characterization of a novel murine model to study Zika virus. Am J Trop Med Hyg. 2016;94:1362–9. https://doi.org/10.4269/ajtmh.16-0111.

25. Dowall SD, Graham VA, Rayner E, Atkinson B, Hall G, Watson RJ, et al. A susceptible mouse model for Zika virus infection. PLoS Negl Trop Dis. 2016;10:e0004658. https://doi.org/10.1371/journal.pntd.0004658.

26. Messias CV, Lemos JP, Cunha DP, Vasconcelos Z, Raphael LMS, Bonaldo MC, et al. Zika virus infects human blood mononuclear cells. BMC Infect Dis. 2019;19:986. https://doi.org/10.1186/s12879-019-4622-y.

27. Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, et al. Correlation of [18F]FLT and [18F]FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:1610–6. https://doi.org/10.1007/s00259-007-0449-9.

28. Deng SM, Zhang W, Zhang B, Chen YY, Li JH, Wu YW. Correlation between the uptake of [18F]fluorodeoxyglucose ([18F]-FDG) and the expression of proliferation-associated antigen Ki-67 in cancer patients: a meta-analysis. PLoS ONE. 2015;10:e0129028. https://doi.org/10.1371/journal.pone.0129028.

29. Fu Y, Maianu L, Melbert BR, Garvey WT. Facilitative glucose transporter gene expression in human lymphocytes, monocytes, and macrophages: a role for GLUT isoforms 1, 3, and 5 in the immune response and foam cell formation. Blood Cells Mol Dis. 2004;32:182–90. https://doi.org/10.1016/j.bcmd.2003.09.002.

30. Simpson IA, Dwyer D, Malide D, Moley KH, Travis A, vanucci SJ. The facilitative glucose transporter GLUT3: 20 years of distinction. Am J Physiol Endocrin Metab. 2008;295:E242–53. https://doi.org/10.1152/ajpendo.90388.2008.

31. Amosse Q, Ceyzeriat K, Tsartalis S, Tournier BB, Millet P. Fluorescence-activated cell sorting-radioligand treated tissue (FACS-RRT) to determine the cellular origin of radioactive signal. J Vis Exp. 2021. https://doi.org/10.3791/62883.

32. Tournier BB, Tsartalis S, Ceyzeriat K, Medina Z, Fraser BH, Gregoire MC, et al. Fluorescence-activated cell sorting to reveal the cell origin of radioligand binding. J Cereb Blood Flow Metab. 2020;40:1242–55. https://doi.org/10.1177/0271678X19860408.

33. Manangseewaran M, Ireland DD, Verthelyi D. Zika (PRVABC59) Infection is associated with T cell infiltration and neurodegeneration in CNS of immunocompetent neonatal C57Bl/6 mice. PLoS Pathog. 2016;12:e1006004. https://doi.org/10.1371/journal.ppat.1006004.

34. Ma W, Li S, Ma S, Jia L, Zhang F, Zhang Y, et al. Zika virus causes testis damage and leads to male infertility in mice. Cell.
Clancy CS, Van Wettere AJ, Morrey JD, Julander JG. Coitus-free sexual transmission of Zika virus in a mouse model. Sci Rep. 2016;8:15379. https://doi.org/10.1038/s41598-018-33528-2.

Smith DR, Hollidge B, Daye S, Zeng X, Blancett C, Kuszpit K, et al. Neuropathogenesis of Zika virus in a highly susceptible immunocompetent mouse model after antibody blockade of type I interferon. PLoS Negl Trop Dis. 2017;11: e0005296. https://doi.org/10.1371/journal.pntd.0005296.

Kuszpit K, Hollidge BS, Zeng X, Stafford RG, Daye S, Zhang X, et al. [18F]DPA-714 PET imaging reveals global neuroinflammation in Zika virus-infected mice. Mol Imaging Biol. 2018;20:275–83. https://doi.org/10.1007/s11307-017-1118-2.

Victorio CBL, Novera W, Tham JY, Watanabe S, Vasudevan SG, Chacko AM. Peptide-conjugated phosphorodiamidate morpholino oligomers for in situ live-cell molecular imaging of dengue virus replication. Int J Mol Sci. 2020;21(23):9260. https://doi.org/10.3390/ijms21239260.

Rose MV, Kjaer ASL, Markova E, Graff J. 18F-FDG PET/CT findings in a patient with Chikungunya virus infection. Diagnostics (Basel). 2017;7(3):49. https://doi.org/10.3390/diagnostics7030049.

Lustberg MB, Aras O, Meisenberg BR. FDG PET/CT findings in acute adult mononucleosis mimicking malignant lymphoma. Eur J Haematol. 2008;81:154–6. https://doi.org/10.1111/j.1600-0609.2008.01088.x.

Orbaek M, Graff J, Markova E, Kronborg G, Lebech AM. 18F-FDG PET/CT findings in acute Epstein-Barr virus infection mimicking malignant lymphoma. Diagnostics (Basel). 2016;6(2):18. https://doi.org/10.3390/diagnostics6020018.

Pan Q, Luo Y, Wu H, Ma Y, Li F. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis mimicking lymphoma on FDG PET/CT. Clin Nucl Med. 2018;43:125–7. https://doi.org/10.1097/RCL.0000000000001923.

Wadih A, Rehm PK, Deng C, Douvas M. Active herpes zoster infection with cutaneous manifestation and adenopathy on FDG PET/CT. Radiol Case Rep. 2015;10:27–9. https://doi.org/10.1016/j.radcr.2015.06.006.

Dyall J, Johnson RF, Chefer S, Leyson C, Thomasson D, Seidel J, et al. [18F]-Fluorodeoxyglucose uptake in lymphoid tissue serves as a predictor of disease outcome in the nonhuman primate model of monkeypox virus infection. J Virol. 2017;91(21):e00897-17. https://doi.org/10.1128/JVI.00897-17.

Dyall J, Johnson RF, Chen DY, Huzella L, Ragland DR, Molura DJ, et al. Evaluation of monkeypox disease progression by molecular imaging. J Infect Dis. 2011;204:1902–11. https://doi.org/10.1093/infdis/jir663.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.